Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
10:05am, Wednesday, 01'st Jul 2026
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
New Strong Sell Stocks for June 30th
06:11am, Tuesday, 30'th Jun 2026
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
12:11pm, Monday, 29'th Jun 2026
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
09:11am, Monday, 29'th Jun 2026
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
08:00am, Monday, 29'th Jun 2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed cl
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
06:59am, Monday, 29'th Jun 2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association Internat
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
09:25am, Friday, 26'th Jun 2026
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
09:21am, Friday, 26'th Jun 2026
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
10:00am, Thursday, 25'th Jun 2026
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact D
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
05:58pm, Tuesday, 23'rd Jun 2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
11:07am, Thursday, 18'th Jun 2026
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
10:55am, Thursday, 18'th Jun 2026
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
10:00am, Thursday, 18'th Jun 2026
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact D
Biogen to acquire RayThera for $1 billion
07:10pm, Wednesday, 17'th Jun 2026
Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
06:59pm, Wednesday, 17'th Jun 2026
Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development Acquisition adds multiple immunology assets to Biogen's portfolio, includi
